Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

SB 9200, a novel agonist of innate immunity, shows potent antiviral activity against resistant HCV variants.

Journal of medical virology - 1 Sept 2017

Jones Meleri, Cunningham Morven E, Wing Peter, DeSilva Sampath, Challa Rupa, Sheri Anjaneyulu, Padmanabhan Seetharamaiyer, Iyer Radhakrishnan P, Korba Brent E, Afdhal Nezam, Foster Graham R

Abstract excerpt

SB 9200 is a novel, first-in-class oral modulator of innate immunity that is believed to act via the activation of the RIG-I and NOD2 pathways. SB 9200 has broad-spectrum antiviral activity against RNA viruses including hepatitis C virus (HCV), norovirus, respiratory syncytial virus, and influenza and has demonstrated activity against hepatitis B virus (HBV) in vitro and in vivo. In phase I clinical trials in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antiviral Agents
Share to NOD2 gene

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genotype

Share to Hepacivirus

Share to Hepatitis C, Chronic

Share to Immunologic Factors

Share to Microbial Sensitivity Tests

Source

Open in PubMed Open full text

Identifiers

PMID: 28303593
DOI: 10.1002/jmv.24809
PMCID: PMC5513743

Genes

NOD2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

SB 9200, a novel agonist of innate immunity, shows potent antiviral activity against resistant HCV variants.PMID 28303593Read ↗

A screen for novel hepatitis C virus RdRp inhibitor identifies a broad-spectrum antiviral compound.Semantic proximity Read ↗

Identification of Interferon Receptor IFNAR2 As a Novel HCV Entry Factor by Using Chemical Probes.Semantic proximity Read ↗

Safety, pharmacokinetics and pharmacodynamics of the oral toll-like receptor 7 agonist GS-9620 in treatment-naive patients with chronic hepatitis C.Semantic proximity Read ↗

Resistance studies of a dithiazol analogue, DBPR110, as a potential hepatitis C virus NS5A inhibitor in replicon systems.Semantic proximity Read ↗

Cross-genotypic examination of hepatitis C virus polymerase inhibitors reveals a novel mechanism of action for thumb binders.Semantic proximity Read ↗

In Vitro Antiviral Activity and Resistance Profile Characterization of the Hepatitis C Virus NS5A Inhibitor Ledipasvir.Semantic proximity Read ↗

Discovery and characterization of substituted diphenyl heterocyclic compounds as potent and selective inhibitors of hepatitis C virus replication.Semantic proximity Read ↗

Preclinical characterization of BMS-791325, an allosteric inhibitor of hepatitis C Virus NS5B polymerase.Semantic proximity Read ↗

Potency and resistance analysis of hepatitis C virus NS5B polymerase inhibitor BMS-791325 on all major genotypes.Semantic proximity Read ↗

Distinct functions of NS5A in hepatitis C virus RNA replication uncovered by studies with the NS5A inhibitor BMS-790052.Semantic proximity Read ↗

Discovery of the first thumb pocket 1 NS5B polymerase inhibitor (BILB 1941) with demonstrated antiviral activity in patients chronically infected with genotype 1 hepatitis C virus (HCV).Semantic proximity Read ↗

A plant-derived flavonoid inhibits entry of all HCV genotypes into human hepatocytes.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.